Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 44

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 44
---
 to June 30, 2025, $50,000 has been paid in cash and $100,000 has been accrued for purposes of payment subsequent to the Closing; (C)Adjustment for $28,452 to record conversion of 754,545 of the NLS’s Preferred Shares pursuant to the securities purchase agreement NLS entered into with three accredited investors on March 27, 2025 into 754,545 NLS Common Shares; (D)Adjustment of $3,771 to record 100,000 NLS Common Shares pursuant to a warrant exchange agreement entered on August 5, 2025, with Alpha. The agreement exchanged a certain common share purchase warrant dated October 10, 2024 to purchase 207,913 of NLS Common Shares previously issued to the Alpha under a securities purchase agreement dated October 9, 2024, between NLS and certain accredited investors, for 100,000 NLS Common Shares; (E)Adjustment to remove $104,963 of interest expenses related to loans converted at the Closing as if Merger took place on January 1, 2024, for the twelve months ended December 31, 2024; (F)Adjustment for the twelve months ended December 31, 2024, of $117,919 to accelerate share -basedcompensation expense for NLS options based on IFRS accounting requirements at the Closing; (G)Adjustment for the six months ended June 30. 2025 of $71,671 to accelerate share -basedcompensation expense for NLS options based on IFRS accounting requirements at the Closing; (H)Adjustment to record elimination of $1,324,178 of share premium and $64,847,190 common stock of Kadimastem at the Closing; (I)Elimination of NLS accumulated deficit of $74,455,306 and accumulated other comprehensive loss of $108,853 at the Closing; (J)Adjustment of $1,901,330 to record issuance of 50,423,799 NLS Common Shares to Kadimastem at CHF 0.03 par value (USD $0.0377) upon the Closing to currently represent 84% currently estimated ownership in NLS; (K) To reflect the preliminary allocation in the unaudited pro forma condensed combined financial statements, management has estimated the purchase price allocation based on currently available information. The carrying value of NLS’s net assets is assumed to